Cost-Effectiveness of Sertindole among Atypical Antipsychotics in the Treatment of Schizophrenia in South Korea Bo-Ra-Mi Kim, MPH, Tae-Jin Lee, PhD, Hye-Jae Lee, MPH, Bo-Hyun Park, PhD, Bong-Min Yang, PhD Value in Health Regional Issues Volume 1, Issue 1, Pages 59-65 (May 2012) DOI: 10.1016/j.vhri.2012.03.015 Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 1 Markov model for cost-effectiveness analysis. Comp +, compliant; Comp −, noncompliant; EPS, extrapyramidal symptoms; M, Markov; Rel +, relapse; Rel −, nonrelapse. Value in Health Regional Issues 2012 1, 59-65DOI: (10.1016/j.vhri.2012.03.015) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 2 Flow of systematic review. RCT, randomized controlled trial. Value in Health Regional Issues 2012 1, 59-65DOI: (10.1016/j.vhri.2012.03.015) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 3 Cost-effectiveness (CE) scatter plot. Value in Health Regional Issues 2012 1, 59-65DOI: (10.1016/j.vhri.2012.03.015) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions